Clicky

Orient Europharma Co Ltd(4120)

Description: Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. The company was founded in 1982 and is based in Taipei, Taiwan.


Keywords: Pharmaceutical Skin Care Immunotherapy Dietary Supplement Clinical Trial Chemotherapy Clinical Research Lotion Toiletry Baby Care Products Head And Neck Cancer Healthcare Supplements Multikine

Home Page: www.oepgroup.com

No. 368, Fu Hsing South Road
Taipei, 106
Taiwan
Phone: 886 2 2755 4881


Officers

Name Title
Mr. Peter Tsai Chairman, CEO & Pres
Phoebe Lee Chief Financial Officer
Liann Lai Director of HR & Admin. Division
Mr. Jack Wu Director

Exchange: TWO

Country: TW : Taiwan

Currency: New Taiwan Dollar (NT$)

Forward PE: 0
Trailing PE: 66.3889
Price-to-Book MRQ: 1.0749
Price-to-Sales TTM: 0.6753
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks